Atypical Hemolytic Uremic Syndrome News and Research

RSS
USPTO grants Taligen patent for TT30 lead product candidate

USPTO grants Taligen patent for TT30 lead product candidate

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome